Protective Effect of Caffeic Acid Phenethyl Ester (CAPE) on Amiodarone-Induced Pulmonary Fibrosisin Rat

Iran J Pharm Res. 2011 Spring;10(2):321-8.

Abstract

Treatment with amiodarone, a commonly prescribed antidysrhythmic agent, is associated with pulmonary fibrosis (PF) which is a commonly progressive and untreatable disease. Caffeic acid phenethyl ester (CAPE) is a phenolic antioxidant and an active anti-inflammatory , anticancer, antimicrobial and antioxidant component of propolis (bee glue; a resinous hive product collected by honey bees). In the current study, the effects of CAPE on amiodarone-induced pulmonary fibrosis in rat were investigated. Male rats were divided in to 4 groups. The first group only received amiodarone (6.25 mg/Kg) on first and third day. The second group received only vehicle (distilled water) with the same volume and in the same time as the first group. The third and fourth groups received amiodarone and were treated with CAPE , 5 and 10 µmol /day respectively, from 2 days before the first dose of amiodarone and until 21 days after the second dose of amiodarone. At the end of treatment course, lung tissue was removed for histopathology and biochemical evaluations. Malondialdehyde (MDA) concentration, myeloperoxidase MPO) and super oxide dismutase (SOD) activities were determined in lung tissue. Histopathological evaluation was performed using light microscopy. MDA level and the activity of myeloperoxidase and superoxide dismutase enzymes significantly decreased in the group which was treated with CAPE (5 µmol/Kg). However, 10 µmol/Kg CAPE had not such an effect. Both doses of CAPE could histopathologically reduce the fibrogenic effects of amiodarone . CAPE was shown to be effective in reducing amiodarone-induced pulmonary fibrosis with the dose of 5 µmol/Kg.

Keywords: Amiodarone; Caffeic acid phenethyl ester; Pulmonary fibrosis; Rat.